Oncology Evolved

Engineering the Next Generation of Off-the-Shelf Cell Therapies

learn about WU-CART

PIPELINE

learn more

PRE-CLINICAL

CLINICAL

CAR-T (Allogeneic)

T-ALL/LBL

T-NHL

AML

Autoimmune

LATEST NEWS

learn more

Wugen Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports manufacturing readiness for therapies with expedited clinical…

U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma

-- Breakthrough Therapy Designation granted to WU-CART-007 (Soficabtagene Geleucel “Sofi-cel”), an allogeneic CAR-T therapy for the treatment of T cell…

Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting

Results from the Phase 1/2 Trial are a Foundation for the Ongoing Pivotal Study of Soficabtagene Geleucel for R/R T-Cell…

OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

About Wugen

Wugen is a clinical-stage biotechnology company

Science

Cellular therapies originating from healthy donors

Contact us

Get in touch with us if you have any questions